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Over the last 15 years, the use of invasive coronary physiology in the catheterization laboratory has demonstrated
favorable outcomes for decision making in patients with intermediate single-vessel stenoses, complex bifurcation and
ostial branch stenoses, multivessel coronary artery disease, and left main stenoses. A recent large multicenter study
(FAME [FFR versus Angiography for Multivessel Evaluation]) found that a physiologically-guided approach was superior
to the standard angiographically-guided approach for percutaneous revascularization in patients with multivessel coro-
nary artery disease. This review addresses selected pertinent concepts and studies supporting the integration of coro-
nary physiology in the catheterization laboratory for optimal patient outcomes. (J Am Coll Cardiol 2010;55:173–85)
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oatients with coronary artery disease (CAD) and myo-
ardial ischemia refractory to medical therapy frequently
ndergo revascularization by percutaneous coronary in-
ervention (PCI) or coronary artery bypass grafting
CABG). When gauging whether ischemia is responsible
or symptoms, clinicians routinely integrate coronary
hysiology into the treatment plan, employing any of a
umber of stress challenges to coronary blood flow
hrough exercise or pharmacologic stimulation, and ob-
erve the associated electrical, perfusion, or functional
yocardial responses. In the last decade, invasive cardi-
logists have used sensor-tipped angioplasty guidewires
n the catheterization laboratory (cath lab) to measure
oronary blood flow and pressure across stenotic artery
egments to determine the ischemic potential of a specific
tenosis.
Integrating invasive coronary physiology with angiog-
aphy has become routine in many but not all cath labs.
ndeed, in the last 15 years, invasive coronary physiologic
tudies have demonstrated favorable outcomes for deci-
ion making in patients with intermediate single-vessel
tenoses (1–3), bifurcation and ostial branch stenoses
4,5), multivessel CAD, and left main stenoses (6 –11).
he following discussion will review selected pertinent
oncepts and studies, with focus on pressure measure-
ents, supporting the integration of coronary physiology
n the cath lab for optimal patient outcomes.
rom the *University of California, Irvine, California; and †Emory University,
tlanta, Georgia. Dr. Kern has served as a speaker for Volcano Therapeutics and St.
ude Medical, manufacturers of pressure guidewires. Dr. Samady has served as a
peaker for Radi Medical/St. Jude Medical and has received a research grant from
olcano Therapeutics.g
Manuscript received April 23, 2009; revised manuscript received May 28, 2009,
ccepted June 9, 2009.ationale for Coronary Physiology
n the Cath Lab
he rationale for physiologic lesion assessment is based on 2
imple facts: 1) the decision to revascularize relies primarily on
he hemodynamic significance of a lesion; and 2) coronary
ngiography frequently fails to identify the accurate hemody-
amic significance of coronary stenoses, particularly those
etween 30% and 80% diameter stenosis (12,13). This failing
as been documented repeatedly by the necessity for stress
esting to clarify the functional (i.e., ischemic) response to
arrowings seen on coronary angiography. Despite sophisti-
ated imaging employing densitometry, rotational angiogra-
hy, and 3-dimensional reconstruction, the anatomic complex-
ty of an atherosclerotic lumen does not reliably reflect the
hysiologic impact on the circulation (Fig. 1). Coronary an-
iography produces 2-dimensional silhouette images of the
-dimensional vascular lumen. Because angiographic stenosis
everity is reported as a ratio of the stenosis’ minimal lumen
iameter to the adjacent “normal” reference segment, accuracy
s limited by the inability to identify both “diseased” and
normal” vessel segments, particularly in the setting of diffuse
AD. In addition, unlike intravascular ultrasound and com-
uterized tomographic angiography, angiography does not
rovide vascular wall detail sufficient to characterize plaque
ize, length, and eccentricity. The eccentric lumen produces
onflicting degrees of angiographic narrowing from different
iewing angulations and introduces uncertainty related to
umen size and its relationship to coronary blood flow (14).
oreover, a long, moderate narrowing can be as or more
emodynamically significant than a short, focal severe narrow-
ng (Fig. 2). Additional artifacts including contrast streaming,
ranch overlap, vessel foreshortening, calcifications, and ostial
rigins further contribute to the uncertainty of the angio-
raphic interpretation.
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Coronary Physiology in the Catheterization Laboratory January 19, 2010:173–85Despite numerous attempts to
evaluate complex anatomy, the
angiographer is still confronted
with a visual dilemma in which
no single view, or even multiple
views, provides an answer. In this
setting, coronary physiologic data
either by noninvasive stress or
invasive physiologic testing is re-
quired to confirm ischemia. If the
noninvasive approach is taken af-
ter angiography, a positive test
will require repeat catheteriza-
tion for PCI, an inefficient ap-
proach for both patients and the
health care system. In contrast,
invasive physiologic testing at the
time of angiography can direct
appropriate revascularization in a
single setting, facilitating opti-
mal patient care.
Fractional Flow Reserve
(FFR) Theory and
Measurement
FFR is defined as the ratio of (i.e.,
percent of normal) flow in the
stenotic artery to the flow in the
same artery in the theoretic ab-
ence of the stenosis (2). Because flow is proportional to
ressure, if resistance is minimal and constant (Ohm’s Law),
ressure can be used as a surrogate of flow during maximal
yperemia, which minimizes resistance. Pressure in a normal
oronary artery is equal to aortic pressure (Pa). Thus, FFR is
imply calculated as the ratio of mean pressure distal (Pd) to a
tenosis to Pa during maximal hyperemia (Fig. 3). In contrast
o coronary flow reserve (CFR) (the ratio of hyperemic to basal
lood flow), FFR has a clear normal value of 1. This is because
ormal epicardial resistance is trivial, and Pa is transmitted
ompletely to the distal artery, making both the numerator and
enominator the same value. An FFR of 0.75 means that the
tenotic vessel only provides 75% of the normal expected flow
n the theoretical absence of the stenosis. In addition, FFR is a
pecific index for the epicardial stenosis. Its derivation attempts
o exclude the confounding influence of the microcirculation,
hanges in hemodynamics, or contractility (15). Unlike CFR,
FR is minimally influenced by conditions known to alter
aseline or maximal hyperemic myocardial blood flow.
The methods of translesional pressure measurement
ave been previously reviewed in detail (16 –18). In brief,
ollowing diagnostic angiography in the cath lab and
sing a technique identical to that of routine angioplasty,
0.014-inch pressure sensor angioplasty guidewire is
nserted through a guiding catheter and into the target
Abbreviations
and Acronyms
ACS  acute coronary
syndrome
CABG  coronary artery
bypass grafting
CAD  coronary artery
disease
Cath lab  catheterization
laboratory
CFR  coronary flow
reserve
FFR  fractional flow
reserve
MACE  major adverse
cardiac events
MI  myocardial infarction
Pa  aortic pressure
PCI  percutaneous
coronary intervention
Pd  mean pressure distal
to a stenosis
QCA  quantitative
coronary angiography
SPECT  single-photon
emission computed
tomography
TIMI  Thrombolysis In
Myocardial Infarctionrtery. Before crossing the stenosis, the sensor wire’s iressure signal is first matched to the aortic (guide
atheter) pressure. The pressure wire is then advanced
cross the lesion. Coronary hyperemia is then induced,
sually with intravenous or intracoronary adenosine (19),
hough papaverine, adenosine triphosphate, or selective
denosine 2A agonists can also be used (20). The Pd and
a are continuously recorded. FFR is then calculated as
d/Pa at maximal hyperemia, the nadir of Pd. An
xample of FFR is shown in Figure 4.
To assess serial lesions or diffuse CAD, the pressure wire can
e pulled back steadily from the distal to proximal vessel
egments during continuous hyperemia induced by intravenous
denosine, papaverine, or adenosine 2A agonists. The pressure
ullback curve can demonstrate either an abrupt change in
istal pressure across a focal narrowing or the gradual pressure
ecovery of diffuse disease without focal obstructions. Tandem
esions in a vessel can also be assessed by the pullback
ecording, treating the most severe gradient-inducing lesion
rst and then reassessing the remaining lesion. In the case of
ost-stent assessment, intravascular ultrasound is recom-
ended for stent apposition because FFR can be normalized
ith unappreciated suboptimal stent deployment.
FFR has prognostic value for late events after bare-metal
tenting (21). Furthermore, FFR measurement of lesions in
he cath lab can complement the anticipated stent diameter
n choosing which lesions may be optimally treated with
are-metal stenting with favorable outcomes (22).
alidation and Threshold of Ischemia
FR values0.75 are associated with ischemic stress testing
n numerous comparative studies with high sensitivity
88%), specificity (100%), positive predictive value (100%),
nd overall accuracy (93%). FFR values0.80 are associated
ith negative ischemic results with a predictive accuracy of
5%. Reports from single stress testing comparisons and
ariations in testing and patients have produced a small zone
f FFR uncertainty (0.75 to 0.80), the use of which requires
linical judgment. A meta-analysis of 31 studies (23) com-
aring the results of FFR to quantitative coronary angiog-
aphy (QCA) and/or noninvasive imaging of the same
esions reported (18 studies, 1,522 lesions) found that QCA
ad a random effects sensitivity of 78% and specificity of
1% against FFR (0.75 cutoff). Compared with noninva-
ive imaging (21 studies, 1,249 lesions), receiver-operating
haracteristic estimates were similar for comparisons of FFR
ith perfusion scintigraphy (976 lesions, sensitivity 75%,
pecificity 77%) and dobutamine stress echocardiography
273 lesions, sensitivity 82%, specificity 74%). Given the
ariances of sensitivity, specificity, positive and negative
redictive accuracy among patients, and types of stress
esting, it is not surprising that, unlike the initial validation
tudy (1) comparing FFR with 3 different stress tests in the
ame patient before and after PCI, this meta-analysis
howed only modest concordance of FFR with noninvasive
maging tests. Furthermore, because perfusion scintigraphy
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January 19, 2010:173–85 Coronary Physiology in the Catheterization Laboratoryompares relative and not absolute myocardial flow in
ifferent coronary beds, scintigraphy, although considered
he clinical gold standard of ischemia, has limitations in
dentifying the hemodynamic significance of individual
esions in patients with multivessel CAD (24,25). Similarly, on
tress echocardiography, severe ischemia in one region may
ask the consequences of a less severe albeit hemodynamically
ignificant lesion in another region. In contrast to noninvasive
ests, FFR is a vessel-specific index of ischemia. Table 1 is a
ummary of important validation studies of FFR (26–36).
Although no longer used for stenosis assessment, a
oppler-tipped sensor guidewire can measure CFR. An
bnormal CFR (2.0) corresponded to reversible myocar-
ial perfusion imaging defects with high sensitivity (86%
o 92%), specificity (89% to 100%), predictive accuracy (89%
o 96%), and positive and negative predictive values (84% to
00% and 77% to 95%, respectively) (37). The uncertainty
f the microcirculatory contribution to an abnormal CFR
akes CFR alone less useful for epicardial lesion assessment
37). Combined pressure and flow data have produced a
ovel set of invasive physiologic tools for epicardial lesion
ssessment such as hyperemic stenosis resistance and for
icrovascular assessment such as index of microcirculatory
esistance (IMR) (38) and hyperemic myocardial resistance.
efined as the hyperemic change in pressure across a
tenosis divided by the hyperemic distal velocity, hyperemic
tenosis resistance may have better predictive value than
Plane 1
Plane 2
Severe 
Why does the ang
Figure 1 Why Does the Angiogram Fail to Predict Physiology?
The angiogram is a 2-dimensional image of 3-dimensional structures. Most interm
angiogram of an eccentric lesion cannot reliably indicate flow adequacy. Other lesi
due to plaque rupture, as demonstrated by intravascular ultrasound cross-sectionFR for detecting noninvasive ischemia (34,39). A sum- 0ary of coronary physiologic measurements and derivations
s provided in Table 2. The American College of Cardiology
nd the American Heart Association have produced a
onsensus statement and guidelines for the physiologic
ssessment of CAD in the cardiac cath lab (37).
utcome of Using FFR for Intermediate Lesions
number of registries have reported low adverse cardiac event
ates at 1 to 2 years after deferral (better stated as nonperfor-
ance) of PCI in patients with moderate stenoses and non-
schemic FFR. The DEFER (FFR to Determine Appropri-
teness of Angioplasty in Moderate Coronary Stenoses) study
andomized 325 patients scheduled for PCI into 3 groups and
eported the 5-year outcomes (40). If FFR was0.75, patients
ere randomly assigned to the deferral group (n 91, medical
herapy for CAD) or the PCI performance group (n  90,
CI with stents). If FFR was 0.75, PCI was performed as
lanned, and patients were entered into the reference group
n  144). Complete follow-up was obtained in 98% of
atients. Overall, the event-free survival was not different
etween the deferred and performed groups (80% and 73%,
espectively, p 0.52), and both were significantly better than
n the reference group (63%, p 0.03). The composite rate of
ardiac death and acute myocardial infarction in the deferred,
erformed, and reference groups was 3.3%, 7.9%, and 15.7%,
espectively (p  0.21 for deferred vs. performed and p 
ings?
m fail?
lesions are oval shaped with 2 diameters, 1 narrow and 1 wide dimension. The
wer right) may appear hazy but widely patent, only to be responsible for angina
ht corner). Figure illustration by Rob Flewell.narrow
iogra
ediate
ons (lo
(far rig.003 for reference vs. both of the deferred and performed
g
p
p
c
p
g
t
(
M
T
i
t
d
w
e
s
s
g
F
t
C
1
s
176 Kern and Samady JACC Vol. 55, No. 3, 2010
Coronary Physiology in the Catheterization Laboratory January 19, 2010:173–85roups) (Fig. 5). The percentage of patients free from chest
ain on follow-up was not different between the deferred and
erformed groups. The 5-year risk of cardiac death or myo-
Figure 2 Factors Producing Resistance to Coronary Blood Flow
The angiographic 2-dimensional images cannot account for the multiple factors that p
eccentric and irregular stenosis (upper panel) shows arrows designating entrance effe
tion of pressure loss (P) across a stenosis (lower right panel) incorporates length (l
laminar separation (f1 and f2) as contributors to resistance and hence pressure loss.
Figure 3 Pressure Signals Used to Calculate FFR
Phasic and mean pressure signals used to measure fractional flow reserve
(FFR), calculated as the ratio of distal coronary pressure (Pd) to aortic pressure
(Pa) at maximal hyperemia, which is equal to 0.78 in this example. For refer-
ence to coronary flow, a velocity signal is shaded and shown at the bottom to
identify the time of maximal hyperemia. The velocity signal is only available in
combined sensor wire studies. Courtesy of Dr. Bernard DeBruyne. CVR  coro-
nary vasodilatory reserve.Fardial infarction (MI) in patients with normal FFR is 1%
er year and is not decreased by stenting. Treating patients
uided by FFR is associated with a low event rate, comparable
o event rates in patients with normal noninvasive testing
Table 3) (41–50).
ultivessel CAD
he COURAGE (Clinical Outcomes Utilizing Revascular-
zation and Aggressive Drug Evaluation) trial (51) reminded us
hat PCI offers no benefit over medical therapy with respect to
eath or MI reduction in low- to intermediate-risk patients
ith multivessel CAD. However, PCI reduced major adverse
vents in the subset of the COURAGE population that had
ignificant ischemia (52). In concert with the COURAGE
tudy, it must be recognized that not all multivessel angio-
raphic CAD is physiologically equivalent CAD. Using
FR to assess all 3 vessels, Sant’Anna et al. (53) have shown
hat the incidence of “significant” 3-vessel angiographic
AD drops from 27% to 9%, 2-vessel drops from 43% to
7%, and single-vessel disease increases from 30% to 60%,
implifying decision making in this difficult patient group.
Early nonrandomized studies demonstrated the benefit of
resistance to coronary blood flow and loss of pressure across a stenosis. The
iction, and zones of turbulence accounting for separation energy loss. The calcula-
s stenosis (As), reference area (An), flow (Q), and coefficients of viscous friction and
illustration by Rob Flewell.roduce
cts, fr
), area
FigureFR guidance in patients with multivessel CAD. Berger
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January 19, 2010:173–85 Coronary Physiology in the Catheterization Laboratoryt al. (54) showed a reduction in major adverse cardiac
vents in 102 patients with multivessel CAD with planned
CI of at least 2 vessels. In 113 coronary arteries with
aseline FFR of 0.57  0.13, PCI was performed, and in
27 coronary arteries with an FFR 0.75 (FFR 0.86 
.06), PCI was not performed. Overall major adverse
ardiac events (MACE) occurred in 9% of patients after 12
onths and 13% after 36 months. In the nontreated vessels,
(6.3%) MACE were reported, whereas 14 (12.3%)
ACE were related to 1 of the initially PCI-treated
oronary arteries. Similarly, in another nonrandomized,
Figure 4 Cine Angiographic Frame of Intermediate Left Anterio
Pressure wire transducer located at arrow. Lower panel shows phasic and mean ao
coronary pressure with significant pressure loss during hyperemia. Fractional flow rese
Physiologic Measurements and Noninvasive StreTable 1 Physiologic Measurements and Non
Index Author (Ref. #) n
FFR
Pijls et al. (2) 60
DeBruyne et al. (26) 60
Pijls et al. (1) 45
Bartunek et al. (27) 37
Abe et al. (28) 46
Chamuleau et al. (29)* 127
Caymaz et al. (30) 40
Jimenez-Navarro et al. (31) 21
Usui et al. (32) 167
Yanagisawa et al. (33) 167
Meuwissen et al. (34) 151
DeBruyne et al. (35) 57
Samady et al. (36) 48
H-SRv
Meuwissen et al. (34) 151
Modified with permission from Kern MJ. Coronary physiology re
Circulation 2000;101:1344–51. *Multivessel disease.BCV  best cut-off value (defined as the value with the highest sum of sen
MI  myocardial infarction; SPECT  single-photon emission computed tomoingle-center trial, FFR-guided PCI (FFR-PCI) was com-
ared with angiographic-guided PCI (Angio-PCI) in 137
atients with multivessel CAD (55). PCI was performed for
ll stenoses with an FFR 0.75. Compared with the
FR-PCI group, there were more vessels per patient treated
n the Angio-PCI group (2.27  0.50 vs. 1.12  0.30
essels) at a higher cost ($3,167  $1,194 vs. $2,572 
934, respectively; p  0.001). The 30-month Kaplan-
eier event-free survival was significantly higher in the
FR-PCI group than in the Angio-PCI group (89% vs.
9%; p  0.01).
cending Coronary Artery Stenosis
d distal
R) is 75/110  0.68.
est Resultsive Stress Test Results
Ischemic Test BCV Accuracy
-ECG 0.74 97
-ECG/SPECT 0.72 85
-ECG/SPECT/pacing/DSE 0.75 93
SE 0.68 90
PECT 0.75 91
PECT 0.74 77
PECT 0.76 95
SE 0.75 90
PECT 0.75 79
PECT 0.75 76
PECT 0.74 85
IBI-SPECT post-MI 0.78 85
IBI-SPECT post-MI 0.78 85
PECT 0.80 87
: practical insights from the cardiac catheterization laboratory.r Des
rtic an
rve (FFss Tinvas
X
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X
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visitedsitivity and specificity); DSE  dobutamine stress echocardiography;
graphy; X-ECG  exercise electrocardiogram.
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Coronary Physiology in the Catheterization Laboratory January 19, 2010:173–85These studies (54,55) led to the larger prospective random-
zed, multicenter FAME (FFR versus Angiography for Mul-
ivessel Evaluation) trial (11). Tonino et al. (11) for the FAME
tudy investigators addressed the hypothesis that a
hysiologically-guided PCI approach (FFR-PCI) was superior
o conventional Angio-PCI in patients with multivessel CAD.
wenty centers in Europe and the U.S. randomly assigned
,005 patients with multivessel CAD undergoing PCI with
rug-eluting stents to 1 of the 2 strategies. Operators selected
ll indicated lesions in advance of randomization for stenting
y visual angiographic appearance (50% diameter stenosis).
or the FFR-PCI group, all lesions had FFR measurements
nd were only stented if the FFR was0.80. The primary end
oints of death, MI, and repeat revascularization (CABG or
Figure 5 Data From the DEFER Study: 5-Year Follow-Up Study
(Left) Event-free survival curves for the Defer, Perform, and Reference groups. (Ri
of cardiac death/myocardial infarction (MI) for the 3 groups. Reprinted, with permi
ntegrated Coronary Physiologic Measurements in the CatheterizatTable 2 Integrated Coronary Physiologic Measurements in the
FFR
Derivation: FFR  Qsten/Qnormal at maximal hyperemia. Q  flow, sten  stenotic
Qsten Psten/Resistancesten
Qnormal  Paorta/Resistancesten, then Qsten/Qnormal  Psten/Paorta
Hence FFR  Pdistal to stenosis/Paorta
(complete derivation includes venous pressure Pv as FFR  Pdistal to stenosis – Pv /
Features: nonischemic threshold range  (0.75–0.80); normal value of 1.0 for eve
maximum blood flow; independent of hemodynamic alterations; value that acc
high spatial resolution (pressure pullback recording)
CFVR
Derivation: CFVR  Qhyperemia/Qbase. Q  velocity if cross-sectional area unchange
Features: Nonischemic threshold range of CFR 2.0; coronary flow reserve in non
coronary endothelial function; accurate estimation of volumetric flow when ves
Combined pressure and flow velocity measurements: for example, HSR
Derivation: HSR  Paorta – Pdistal to stenosis/hyperemic Q
Features: Separate assessment of stenosis and microvascular resistances; allows
hemodynamic gain after PCI)
For Stenosis Resistance Index: Nonischemic threshold values 0.8 mm Hg/cm/s
useful in cases of discordance between CFR and FFR
FR  coronary flow reserve; CFVR  coronary flow velocity reserve; FFR  fractional flow reservCI) were obtained at 1 year. Of the 1,005 patients, 496 were
ssigned to the Angio-PCI group, and 509 were assigned to
he FFR-PCI group. Clinical characteristics and angiographic
ndings were similar in both groups. The Syntax (Synergy
etween PCI with Taxus and Cardiac Surgery) scores for
auging risk in multivessel disease involvement were identical
t 14.5, indicating low-intermediate risk patients.
Despite identifying in advance 3 angiographically indi-
ated lesions per patient for stenting, compared with the
ngio-PCI group, the FFR-PCI group used fewer stents
er patient (1.9  1.3 vs. 2.7  1.2, p  0.001), less
ontrast (272 ml vs. 302 ml, p  0.001), had lower
rocedure cost ($5,332 vs. $6,007, p  0.001), and shorter
ospital stay (3.4 days vs. 3.7 days, p  0.05). More
cidence
from Pijls et al. (40).
aboratoryeterization Laboratory
, normal  theoretic same artery without stenosis
Pv, see Pijls et al. [2])
ery and every patient; epicardial lesion specific; linear relation with relative
for total myocardial blood flow, including collaterals; highly reproducible;
ng hyperemia
cted vessels assesses microvascular integrity; useful for studies of
ss-sectional area available
uction of pressure flow curves (assessment of compliant lesions,
al value of 0; lesion specific; highly reproducible; high sensitivity;
 hyperemic stenosis resistance; PCI  percutaneous coronary intervention.ght) In
ssion,ion LCath
artery
Paorta –
ry art
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d duri
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sel cro
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January 19, 2010:173–85 Coronary Physiology in the Catheterization Laboratorymportantly, at 1-year follow-up, the FFR-PCI group had
ewer MACE (13.2% vs. 18.4%, p 0.02), fewer combined
eath or MI (7.3% vs. 11%, p  0.04), and a lower total
umber of MACE (76 vs. 113, p  0.02) compared with
he Angio-PCI group (Fig. 6).
FAME used an FFR ischemic cutoff value of 0.80. It is
ossible that some lesions with FFR between 0.75 and 0.79
hat had PCI could have been treated medically, but the
utcomes still remained positive for the FFR-PCI strategy.
he precise mechanisms of reduced end points in the
FR-guided arm of FAME are not known, but are likely
ssociated with fewer implanted stents having fewer
rocedure-related early (e.g., side branch occlusion, addi-
ional troponin release) and late stent complications (e.g.,
ubacute thrombosis, restenosis). This study is a substantial
linical validation of the preceding FFR outcome studies in
ingle and multivessel disease patients from single centers
nd has important implications for managing CAD patients
ntegrating physiology for the best long-term results. Figure
shows an example of a patient with multivessel disease
reated on the basis of an FFR-guided PCI strategy.
eft Main Stenosis
orrect clinical assessment of left main stem CAD lesions is of
ivotal importance. On the basis of angiographic information
lone, this evaluation often cannot be done reliably. Limited
ata suggest that FFR supports decision making in equivocal
eft main disease. In a prospective single-center follow-up
tudy, Bech et al. (6) studied 51 patients with intermediate or
mbiguous left main CAD. If FFR was 0.75, surgical
evascularization (CABG) was recommended; if FFR was
0.80, medical treatment for the left main with PCI elsewhere
s indicated was performed. If FFR was in the “gray zone”
Outcomes After FFR-Based Deferralof Coronary Intervention in Intermediate CoronaTable 3 Outcomes After FFR-Based Deferralof Coronary Intervention in Intermed
Index Author (Ref. #) n
FFR
Bech et al. (41) 100
Hernandez Garcia et al. (42) 43
Bech et al. (43) 60
Bech et al. (6)* 24
Rieber et al. (44) 47
Chamuleau et al. (45) 92
Rieber et al. (46) 24
Leesar et al. (47)† 34
Pijls et al. (40) 325
CFR
Kern et al. (48) 88
Ferrari et al. (49) 22
Chamuleau et al. (50)‡ 143
Modified with permission from Kern MJ. Coronary physiology revisite
2000;101:1344–51. *Left main stenosis. †unstable angina pectoris
MACE  major adverse cardiac events (principally rates of perc
infarction); other abbreviations as in Table 2.0.75 and 0.80), treatment was dependent on additional Fndividual criteria. Of 51 patients, CABG was performed in 27
atients (53%). The remaining 24 patients (47%) were treated
onsurgically. Estimated survival after 4 years of follow-up was
1% among CABG patients and 100% among patients in the
onsurgical group. Event-free survival was 66% in the CABG
roup and 69% in the nonsurgical group. In the largest cohort
o date, Courtis et al. (56) studied 142 consecutive patients
ith intermediate left main coronary artery stenosis (42 13%
iameter). Those patients with FFR 0.80 (n  82) were
reated medically; those patients with FFR 0.75 (n  60)
nderwent CABG. MACE at 14 months’ follow-up was 13%
nd 7%, respectively (p 0.27). Cardiac death or MI was also
imilar (6% and 7%, p  0.70). FFR appears helpful in
dentifying patients with intermediate left main disease suitable
or surgical revascularization or continued medical therapy,
ith excellent survival and low event rates (57). Figure 8 shows
n example of a patient with moderate left main disease
valuated physiologically.
FR and Ostial Branch Assessment
stial narrowings, especially in side branches within stents
called “jailed” branches), are particularly difficult to assess
y angiography because of the overlap orientation relative to
he parent branch, stent struts across the branch, and image
oreshortening. Koo et al. (58) compared FFR with QCA in
7 “jailed” side branch lesions (vessel size2.0 mm, percent
tenosis 50% by visual estimation) after stent implanta-
ion. No lesion with 75% stenosis had FFR 0.75.
mong 73 lesions with 75% stenosis, only 20 lesions
27%) were functionally significant. Koo et al. (58) also
eported the 9-month outcome of FFR-guided side branch
CI strategy for bifurcation lesions. Of the 91 patients, side
ranch intervention was performed in 26 of 28 patients with
sions
Coronary Lesions
efer Value MACE (%) Follow-Up (Months)
0.75 8 18
0.75 12 11
0.75 12 24
0.75 21 29
0.75 13 12
0.75 9 12
0.75 8 12
0.75 9 12
0.75 3 60
2.0 7 9
2.0 9 15
2.0 6 12
ical insights from the cardiac catheterization laboratory. Circulation
tivessel disease.
us coronary intervention; no significant rates of death/myocardialry Le
iate
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unctional restenosis was 8% (5 of 65), with no difference in
vents compared with 110 side branches treated by angiog-
aphy alone (4.6% vs. 3.7%, p 0.7) (Fig. 9). Measurement
f FFR for ostial and side branch assessment identifies a
inority of lesions that are functionally significant (4,5,58).
FR and CABG Conduit Patency
lthough most surgical recommendations for patients with
ultivessel disease are to bypass all lesions with 50% diam-
ter narrowing, the patency rate of saphenous vein grafts on
essels with hemodynamically nonsignificant lesions has been
uestioned. Botman et al. (59) found that there was a 20% to
5% incidence of graft closure in 450 CABGs when placed on
onhemodynamically significantly stenosed arteries (pre-
perative FFR 0.80) at 1 year of follow-up (Fig. 10).
lthough the precise mechanisms of graft closure remain
nder study, it is postulated that coronary blood flow favors the
ower resistance path through the native (relatively) nonob-
Figure 6 Data From the FAME Study: Kaplan-Meier Survival Cu
(A) Event-free survival for major adverse cardiac events was significant at 1 year.
myocardial infarction (C), or coronary artery bypass grafting/percutaneous coronartructed arteries rather than vein grafts, with slower or com- Hetitive graft flow promoting premature graft closure (60). In
atients requiring CABG for multivessel revascularization,
ngiographic lesions of uncertain significance would benefit
rom FFR, providing prognostic information regarding poten-
ial of future bypass graft patency. FFR has serious implications
or best long-term CABG outcomes.
FR and Acute Coronary Syndrome (ACS)
he pathophysiology of the infarct-related artery and bed
fter MI is complex. Because of the dynamic nature of
atients with ACS, particularly MI, the predictive ability of
FR has some theoretic limitations. In ACS, the microvas-
ular bed in the infarct zone may not have uniform,
onstant, or minimal resistance. The stenosis may also
volve as thrombus and vasoconstriction abate. FFR mea-
urements are not meaningful when angiographic reperfu-
ion (i.e., Thrombolysis In Myocardial Infarction [TIMI]
ow grade 3) has not been achieved in the artery. FFR has
imited use in the infarct-related artery in the acute setting.
for 1-Year Follow-Up of the FAME Patients
erences in event-free survival for death (B),
vention (PCI) (D). Reprinted, with permission, from Tonino et al. (11).rves
No diff
y interowever, FFR has value in lesion assessment in the
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emote noninfarct-related vessels.
To address the utility of measurements days after MI,
eBruyne et al. (35) compared single-photon emission
omputed tomography (SPECT) myocardial perfusion im-
ging and FFR obtained before and after PCI in 57 MI
atients 6 days (mean 20 days) before evaluation. Patients
Figure 7 FFR in Multivessel PCI Decision Making
(A) Cine angiograms and FFR in a patient undergoing multivessel assessment. (Le
(OM1) shows FFR  0.76. (Right) Left anterior descending artery (LAD) FFR  0.8
of PCI guided by FFR. Abbreviations as in Figure 1.ith positive SPECT before PCI had a significantly lower tFR than patients with negative SPECT (0.52  0.18 vs.
.67  0.16; p  0.0079), but a significantly higher left
entricular ejection fraction (63  10% vs. 52  10%; p 
.0009) despite a similar percent diameter stenosis (67 
3% vs. 68  16%; p  NS). The sensitivity and specificity
f FFR of 0.75 to detect a defect on SPECT were 82%
nd 87%, respectively. When only truly positive and nega-
ht coronary artery with diffuse severe disease. (Middle) First obtuse marginal
rvention on right coronary artery, OM, was performed. (B) Angiographic resultsft) Rig
5. Inteive SPECT imaging was considered, the corresponding
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utoff for determining peri-infarct ischemia was 0.78. Of
ote, a significant inverse correlation was found between left
entricular ejection fraction and FFR (r 0.29, p 0.049),
uggesting a relationship between FFR and the mass of
iable myocardium. For patients who are 6 days after an
nfarction, FFR accurately reflects the hemodynamic sever-
Figure 8 Cine Frame of Intermediate Left Main Narrowing
Fractional flow reserve (FFR) was 0.87. Medical therapy was recommended. Pa 
Figure 9 FFR and Jailed Side Branch Follow-Up
Serial changes of fractional flow reserve (FFR) in the side branch vessel of 22
bifurcation lesions after stenting main vessel (Post-stent), after kissing balloon
inflation of main vessel and side branch (Post-KB), and at 6 months’ follow-up.
Reprinted, with permission, from Koo et al. (58).sty of a lesion and its impact on myocardial perfusion despite
he damaged microvasculature in the infarct bed.
In a similar study and relevant to clinical practice in the
.S., where AMI patients often present early for angio-
raphic evaluation day 1 to 4 post-infarction, McClish et al.
61) found similar FFR in 43 vessels subtending recent
nfarct beds compared with 25 control vessels, matched by
esion length and minimal luminal diameter, in patients
ithout infarcts (0.67  17 vs. 0.68  17, p  NS).
owever, noninvasive physiologic evaluation was not per-
ormed. Therefore, in a subsequent study, Samady et al. (36)
ompared FFR with SPECT and myocardial contrast echo
n 48 patients 3.7  1.3 days after infarction. To identify
rue reversibility, follow-up SPECT was performed 11
eeks after PCI. The sensitivity, specificity, and concor-
ance of FFR 0.75 for detecting true reversibility on
PECT were 88%, 93%, and 91% (chi-square p  0.001)
nd for detecting reversibility on myocardial contrast echo
ere 90%, 100%, and 93% (chi-square p  0.001), respec-
ively (Fig. 11). The optimal FFR value for discriminating
nducible ischemia on noninvasive imaging was also 0.78,
imilar to DeBruyne et al. (35).
Fearon et al. (38) found that patients with preserved IMR
fter primary angioplasty may have greater recovery of
egional ventricular function after primary angioplasty for
T-segment elevation myocardial infarction. In addition to
roviding prognostic information in this important patient
pressure; Pd  mean pressure distal to a stenosis.aorticubset, IMR may potentially be used in selecting patients
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ight most benefit from regional delivery of regenerative
ell therapies.
The use of FFR to reduce cost in ACS patient manage-
ent was reported by Leesar et al. (62), who randomized 70
atients with recent unstable angina or non–ST-segment
levation myocardial infarction with intermediate single-
essel stenosis to 1 of 2 strategies: angiography followed by
PECT the next day or FFR-guided revascularization at the
ime of angiography. Compared with the SPECT strategy,
he FFR-guided approach had a reduced hospital duration
11 2 h vs. 49 5 h, p 0.001) and cost (U.S. $1,329 $44
s. $2,113 $120, p 0.05), with no increase in procedure
ime, radiation exposure time, or clinical event rates at 1 year
f follow-up. Similarly, Potvin et al. (63) evaluated 201
onsecutive patients (62% with unstable angina or MI) in
hom revascularization was guided by FFR. At 11  6
onths of follow-up, cardiac events occurred in 20 patients
10%), and no significant differences were observed between
atients with unstable angina or MI and those with stable
Figure 10 Relationship Between 1-Year Graft
Patency and % Diameter Stenosis and FFR
(A) The relationship between angiographic stenosis severity and graft failure
after angiographic follow-up at 1 year. (B) The relation between functional ste-
nosis severity established by fractional flow reserve (FFR) measurements and
graft failure at angiographic follow-up after 1 year. Reprinted, with permission,
from Botman et al. (59).ngina (9% vs. 13%, p  0.44). Finally, Fischer et al. (64)ound similar MACE rates at 12 months in patients with
n  35) and without (n  85) ACS in whom revascular-
zation was guided by FFR (15% vs. 9%, p  NS).
ummary
ntegrating coronary physiology in the cardiac cath lab,
rincipally using FFR, represents a precise and powerful
djunctive tool complimenting angiography and providing
Figure 11 FFR, SPECT, and MCE in the
Early Post-Myocardial Infarction Patient
(A) Concordance between fractional flow reserve (FFR) and single-photon emis-
sion computed tomography (SPECT) (dipyridamole-stress paired with rest imag-
ing). (B) Concordance between FFR and myocardial contrast echo (MCE). (C)
Sensitivity and specificity curves of FFR for detecting reversibility of combined
noninvasive testing in patients with acute coronary syndrome. Reprinted, with
permission, from Samady et al. (36). DS  diameter stenosis.
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Coronary Physiology in the Catheterization Laboratory January 19, 2010:173–85bjective data about specific lesions and their ischemic
otential. FFR is considered one of the standards for
unctional assessment of CAD, acting as a stress test within
he cardiac cath lab environment. Although the cost of the
hysiologic information translates into an operational ex-
ense for the cath lab, the data identify significant overall
avings to the health care system and a substantial clinical
enefit to the patient.
Although FFR use in the cath lab has steadily grown over
he past decade, and given the strong case for favorable
utcomes, it is surprising that FFR is not more widely
pplied. Reluctance to adopt the technique is multifactorial,
ncluding habit, bias, training experience, practice pressures
f patient throughput, financial incentives, and misconcep-
ions by patients, families, and referring physicians regard-
ng the perceived need to stent CAD. FFR technology
urdles of cumbersome set-up time, accurate hemodynam-
cs, and dosing of adenosine have contributed to slow
doption of FFR in some laboratories. These issues have
een overcome in laboratories with insightful physician and
ath lab team member concept adopters. Physiologic data
cquired during the angiographic procedure can facilitate
imely, clinically, and economically sound decision making
o direct revascularization options for best patient outcomes.
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